Vertex Pharmaceuticals Incorporated Stock Price, News & Analysis (NASDAQ:VRTX)

$147.41 -0.53 (-0.36 %)
(As of 11/20/2017 01:42 PM ET)
Previous Close$147.94
Today's Range$146.65 - $148.79
52-Week Range$71.46 - $167.85
Volume903,500 shs
Average Volume1.81 million shs
Market Capitalization$37.28 billion
P/E Ratio245.68
Dividend YieldN/A
Beta1.63

About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated logoVertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:VRTX
  • CUSIP: 92532F10
  • Web: www.vrtx.com
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 3.28%
  • Quick Ratio: 3.14%
Price-To-Earnings:
  • Trailing P/E Ratio: 245.68
  • Forward P/E Ratio: 204.74
  • P/E Growth: 3.74
Sales & Book Value:
  • Annual Sales: $1.70218 billion
  • Price / Sales: 21.90
  • Cash Flow: $0.14 per share
  • Price / Cash: 1,049.31
  • Book Value: $5.39 per share
  • Price / Book: 27.35
Profitability:
  • Trailing EPS: $0.78
  • Net Income: ($112,050,000.00)
  • Net Margins: 8.53%
  • Return on Equity: 9.23%
  • Return on Assets: 5.01%
Misc:
  • Employees: 2,150
  • Outstanding Shares: 252,900,000
 

Frequently Asked Questions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

What is Vertex Pharmaceuticals Incorporated's stock symbol?

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

How were Vertex Pharmaceuticals Incorporated's earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings results on Wednesday, October, 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.49. The pharmaceutical company had revenue of $578.20 million for the quarter, compared to analysts' expectations of $522.07 million. Vertex Pharmaceuticals Incorporated had a return on equity of 9.23% and a net margin of 8.53%. The business's revenue was up 39.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.16 earnings per share. View Vertex Pharmaceuticals Incorporated's Earnings History.

When will Vertex Pharmaceuticals Incorporated make its next earnings announcement?

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for Vertex Pharmaceuticals Incorporated.

Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?

25 brokers have issued 12 month price targets for Vertex Pharmaceuticals Incorporated's stock. Their forecasts range from $85.00 to $205.00. On average, they expect Vertex Pharmaceuticals Incorporated's share price to reach $172.74 in the next twelve months. View Analyst Ratings for Vertex Pharmaceuticals Incorporated.

What are Wall Street analysts saying about Vertex Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

  • 1. Maxim Group analysts commented, "The Winter Olympics are coming this February and what do the judges want to see? A triple…Will Vertex score a perfect 10? We’ll see as two triples go pivotal and more P2 2 data, which has already impressed, comes in early 2018." (10/26/2017)
  • 2. According to Zacks Investment Research, "Vertex has two cystic fibrosis (CF) drugs – Kalydeco & Orkambi – in its portfolio with blockbuster potential. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase the patient population and boost sales. Vertex’s CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Investor focus is on triple combination CF regimens, which are crucial for long-term growth at Vertex as they have the potential to treat up to 90% of CF patients.  The stock has also shot up so far this year. Estimates have also gone up slightly ahead of the company’s Q3 earnings release. The company has a positive record of earnings surprises in recent quarters. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Orkambi’s EU reimbursement remains a key for sales growth in 2H17." (10/24/2017)
  • 3. Cowen and Company analysts commented, "Vertex announced that the FDA has approved Kalydeco for use in CF patients over the." (8/1/2017)
  • 4. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)

Who are some of Vertex Pharmaceuticals Incorporated's key competitors?

Who are Vertex Pharmaceuticals Incorporated's key executives?

Vertex Pharmaceuticals Incorporated's management team includes the folowing people:

  • Jeffrey M. Leiden M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 61)
  • Thomas Graney, Chief Financial Officer, Senior Vice President (Age 52)
  • Ian F. Smith CPA, Chief Operating Officer, Executive Vice President (Age 51)
  • Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer (Age 42)
  • David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer (Age 52)
  • Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer (Age 51)
  • Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer (Age 61)
  • Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO (Age 49)
  • Paul M. Silva, Senior Vice President, Corporate Controller (Age 51)
  • Bruce I. Sachs, Lead Director, Independent Director (Age 57)

Who owns Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (2.38%), Ameriprise Financial Inc. (2.15%), Orbimed Advisors LLC (0.82%), Bank of New York Mellon Corp (0.79%), Wells Fargo & Company MN (0.78%) and Amundi Pioneer Asset Management Inc. (0.50%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals Incorporated.

Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Manning & Napier Advisors LLC, Pictet Asset Management Ltd., State of Wisconsin Investment Board, Perceptive Advisors LLC, Prudential Financial Inc., First Trust Advisors LP and Russell Investments Group Ltd.. Company insiders that have sold Vertex Pharmaceuticals Incorporated company stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Point72 Asset Management L.P., Assenagon Asset Management S.A., Janus Henderson Group PLC, First Quadrant L P CA, Crawford Lake Capital Management LLC, Picton Mahoney Asset Management and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

How do I buy Vertex Pharmaceuticals Incorporated stock?

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals Incorporated's stock price today?

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $147.41.

How big of a company is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated has a market capitalization of $37.28 billion and generates $1.70218 billion in revenue each year. The pharmaceutical company earns ($112,050,000.00) in net income (profit) each year or $0.78 on an earnings per share basis. Vertex Pharmaceuticals Incorporated employs 2,150 workers across the globe.

How can I contact Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated's mailing address is 50 Northern Ave, BOSTON, MA 02210-1862, United States. The pharmaceutical company can be reached via phone at +1-617-3416393 or via email at [email protected]


MarketBeat Community Rating for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  996 (Vote Outperform)
Underperform Votes:  543 (Vote Underperform)
Total Votes:  1,539
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 23 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $172.74 (17.18% upside)

Consensus Price Target History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Price Target History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
10/27/2017Needham & Company LLCReiterated RatingBuy$195.00N/AView Rating Details
10/27/2017Robert W. BairdReiterated RatingBuyN/AView Rating Details
10/26/2017HC WainwrightReiterated RatingHold$85.00N/AView Rating Details
10/26/2017Maxim GroupReiterated RatingBuy$195.00N/AView Rating Details
10/26/2017Piper Jaffray CompaniesReiterated RatingOverweight$205.00N/AView Rating Details
9/29/2017DA DavidsonInitiated CoverageBuy$200.00LowView Rating Details
9/29/2017BTIG ResearchInitiated CoverageBuy -> Buy$200.00MediumView Rating Details
9/27/2017BMO Capital MarketsReiterated RatingBuyLowView Rating Details
8/22/2017Jefferies Group LLCReiterated RatingBuyHighView Rating Details
8/1/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
8/1/2017ArgusBoost Price TargetBuy$71.46 -> $175.00LowView Rating Details
7/27/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$150.00 -> $175.00MediumView Rating Details
7/27/2017J P Morgan Chase & CoSet Price TargetBuy$175.00 -> $184.00HighView Rating Details
7/22/2017Morgan StanleyReiterated RatingOverweight$153.00 -> $190.00LowView Rating Details
7/21/2017Citigroup Inc.Reiterated RatingBuy$135.00 -> $190.00LowView Rating Details
7/19/2017Credit Suisse GroupBoost Price TargetOutperform$125.00 -> $195.00HighView Rating Details
7/19/2017JMP SecuritiesReiterated RatingOutperformHighView Rating Details
7/19/2017Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$181.00HighView Rating Details
7/19/2017Janney Montgomery ScottUpgradeNeutral -> Buy$98.00HighView Rating Details
7/19/2017Barclays PLCUpgradeEqual Weight -> Overweight$115.00 -> $180.00HighView Rating Details
7/18/2017Stifel NicolausBoost Price TargetBuy -> Buy$130.00 -> $154.00HighView Rating Details
6/22/2017Leerink SwannReiterated RatingOutperformMediumView Rating Details
6/2/2017CIBCUpgradeMarket Perform -> OutperformLowView Rating Details
5/19/2017Bank of America CorporationReiterated RatingNeutral$121.00 -> $125.00LowView Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00N/AView Rating Details
4/28/2016Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$109.00 -> $88.00N/AView Rating Details
3/28/2016GuggenheimLower Price TargetBuy$145.00 -> $114.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Earnings by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Earnings History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018$0.47N/AView Earnings Details
10/25/2017Q3 2017$0.04$0.53$522.07 million$578.20 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.06$0.39$489.95 million$544.10 millionViewN/AView Earnings Details
4/27/2017Q1 2017$0.04$0.13$692.64 million$714.72 millionViewN/AView Earnings Details
1/25/2017Q4 2016$0.29$0.35$453.40 million$458.71 millionViewN/AView Earnings Details
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
2017 EPS Consensus Estimate: $0.57
2018 EPS Consensus Estimate: $1.70
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.02)$0.04$0.02
Q2 20174$0.02$0.11$0.07
Q3 20173$0.07$0.17$0.11
Q4 20173$0.23$0.56$0.37
Q1 20181$0.30$0.30$0.30
Q2 20181$0.36$0.36$0.36
Q3 20181$0.47$0.47$0.47
Q4 20181$0.57$0.57$0.57
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/29/2013quarterly$0.402/20/20133/13/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 92.42%
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Institutional Ownership by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017Stuart A ArbuckleEVPSell221$147.29$32,551.09View SEC Filing  
11/6/2017Ian F SmithCOOSell6,405$150.00$960,750.00View SEC Filing  
11/6/2017Stuart A ArbuckleEVPSell4,250$148.17$629,722.50View SEC Filing  
11/3/2017Ian F SmithCOOSell2,155$150.00$323,250.00View SEC Filing  
11/3/2017Jeffrey ChodakewitzCMOSell5,390$144.71$779,986.90View SEC Filing  
11/3/2017Michael PariniEVPSell2,330$149.50$348,335.00View SEC Filing  
11/3/2017Sangeeta N BhatiaDirectorSell7,073$143.05$1,011,792.65View SEC Filing  
10/31/2017Amit SachdevEVPSell40,000$145.05$5,802,000.00View SEC Filing  
10/31/2017Ian F SmithCOOSell75,000$145.06$10,879,500.00View SEC Filing  
10/31/2017Jeffrey ChodakewitzCMOSell60,000$145.05$8,703,000.00View SEC Filing  
10/27/2017Stuart A ArbuckleEVPSell6,290$143.97$905,571.30View SEC Filing  
10/16/2017Ian F SmithCOOSell2,125$155.61$330,671.25View SEC Filing  
10/16/2017Jeffrey ChodakewitzCMOSell1,718$155.19$266,616.42View SEC Filing  
10/12/2017Michael PariniEVPSell2,125$152.93$324,976.25View SEC Filing  
10/2/2017Jeffrey ChodakewitzCMOSell3,437$151.64$521,186.68View SEC Filing  
8/31/2017David AltshulerEVPSell1,796$160.00$287,360.00View SEC Filing  
8/7/2017Ian F SmithCFOSell4,250$155.39$660,407.50View SEC Filing  
8/7/2017Paul M SilvaSVPSell1,289$152.88$197,062.32View SEC Filing  
8/3/2017Jeffrey ChodakewitzCMOSell5,390$154.17$830,976.30View SEC Filing  
8/3/2017Michael PariniEVPSell2,330$155.72$362,827.60View SEC Filing  
8/2/2017Ian F SmithCFOSell2,155$154.17$332,236.35View SEC Filing  
8/2/2017Jeffrey ChodakewitzCMOSell1,796$154.13$276,817.48View SEC Filing  
8/2/2017Paul M SilvaSVPSell1,289$151.80$195,670.20View SEC Filing  
7/31/2017Jeffrey M LeidenCEOSell11,063$152.81$1,690,537.03View SEC Filing  
7/31/2017Paul M SilvaSVPSell860$152.99$131,571.40View SEC Filing  
7/31/2017Stuart A ArbuckleEVPSell2,125$152.99$325,103.75View SEC Filing  
7/21/2017Amit SachdevEVPSell28,625$160.93$4,606,621.25View SEC Filing  
7/21/2017Ian F SmithCFOSell133,750$160.98$21,531,075.00View SEC Filing  
7/21/2017Jeffrey ChodakewitzCMOSell46,733$160.96$7,522,143.68View SEC Filing  
7/21/2017Jeffrey M LeidenCEOSell216,624$160.96$34,867,799.04View SEC Filing  
7/21/2017Paul M SilvaSVPSell43,443$161.07$6,997,364.01View SEC Filing  
7/19/2017Michael PariniEVPSell10,829$161.00$1,743,469.00View SEC Filing  
7/17/2017Jeffrey ChodakewitzCMOSell573$129.85$74,404.05View SEC Filing  
7/3/2017Jeffrey ChodakewitzCMOSell3,438$127.80$439,376.40View SEC Filing  
6/21/2017Jeffrey ChodakewitzCMOSell5,157$132.87$685,210.59View SEC Filing  
6/21/2017Paul M SilvaSVPSell2,577$133.36$343,668.72View SEC Filing  
6/5/2017David AltshulerEVPSell7,500$130.00$975,000.00View SEC Filing  
6/2/2017Jeffrey M LeidenCEOSell147,101$129.50$19,049,579.50View SEC Filing  
6/2/2017Sangeeta N BhatiaDirectorSell1,176$128.44$151,045.44View SEC Filing  
6/2/2017Stuart A ArbuckleEVPSell70,969$128.06$9,088,290.14View SEC Filing  
5/2/2017Jeffrey ChodakewitzCMOSell8,979$121.05$1,086,907.95View SEC Filing  
4/28/2017Jeffrey M LeidenCEOSell157,200$119.50$18,785,400.00View SEC Filing  
4/5/2017Jeffrey ChodakewitzCMOSell8,021$114.00$914,394.00View SEC Filing  
4/3/2017Jeffrey ChodakewitzCMOSell2,291$108.85$249,375.35View SEC Filing  
3/29/2017Amit SachdevEVPSell80,500$107.63$8,664,215.00View SEC Filing  
3/29/2017Jeffrey ChodakewitzCMOSell13,750$106.65$1,466,437.50View SEC Filing  
3/29/2017Paul M SilvaSVPSell1,688$106.30$179,434.40View SEC Filing  
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.76View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.39View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.00View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.84View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.25View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.00View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.00View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.00View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.00View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.00View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.00View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.00View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.00View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.72View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.84View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.00View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.91View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.00View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.90View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Source:
DateHeadline
Galapagos CF Candidate Shows Potential in Phase II Study - NasdaqGalapagos' CF Candidate Shows Potential in Phase II Study - Nasdaq
www.nasdaq.com - November 20 at 12:07 PM
Galapagos' CF Candidate Shows Potential in Phase II StudyGalapagos' CF Candidate Shows Potential in Phase II Study
finance.yahoo.com - November 20 at 12:07 PM
Vertex Pharmaceuticals Incorporated (VRTX) Given Average Rating of "Buy" by AnalystsVertex Pharmaceuticals Incorporated (VRTX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 19 at 7:56 AM
Stuart A. Arbuckle Sells 221 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockStuart A. Arbuckle Sells 221 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock
www.americanbankingnews.com - November 17 at 9:28 PM
Strong Sales Growth Make Vertex Pharmaceuticals (VRTX) a BuyStrong Sales Growth Make Vertex Pharmaceuticals (VRTX) a Buy
investorplace.com - November 13 at 5:11 PM
ETFs with exposure to Vertex Pharmaceuticals, Inc. : November 13, 2017ETFs with exposure to Vertex Pharmaceuticals, Inc. : November 13, 2017
finance.yahoo.com - November 13 at 4:50 PM
Vertex Gets CHMP Recommendation for Orkambi Label ExpansionVertex Gets CHMP Recommendation for Orkambi Label Expansion
finance.yahoo.com - November 13 at 4:50 PM
Vertex Is a Rare-Disease PowerhouseVertex Is a Rare-Disease Powerhouse
finance.yahoo.com - November 13 at 11:14 AM
Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European UnionVertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union
finance.yahoo.com - November 12 at 1:14 PM
Vertex Pharmaceuticals Incorporated (VRTX) Expected to Announce Quarterly Sales of $592.47 MillionVertex Pharmaceuticals Incorporated (VRTX) Expected to Announce Quarterly Sales of $592.47 Million
www.americanbankingnews.com - November 8 at 4:50 AM
Ian F. Smith Sells 2,155 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockIan F. Smith Sells 2,155 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock
www.americanbankingnews.com - November 7 at 6:48 PM
Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells 4,250 Shares of StockInsider Selling: Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells 4,250 Shares of Stock
www.americanbankingnews.com - November 7 at 6:46 PM
Michael Parini Sells 2,330 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockMichael Parini Sells 2,330 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock
www.americanbankingnews.com - November 7 at 6:46 PM
Ian F. Smith Sells 6,405 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockIan F. Smith Sells 6,405 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock
www.americanbankingnews.com - November 7 at 6:46 PM
Sangeeta N. Bhatia Sells 7,073 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockSangeeta N. Bhatia Sells 7,073 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock
www.americanbankingnews.com - November 7 at 6:33 PM
Vertex Pharmaceuticals (VRTX) a Buy on Strong Sales GrowthVertex Pharmaceuticals (VRTX) a Buy on Strong Sales Growth
investorplace.com - November 6 at 8:43 PM
$0.58 EPS Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter$0.58 EPS Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter
www.americanbankingnews.com - November 6 at 7:30 PM
Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells 5,390 Shares of StockInsider Selling: Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells 5,390 Shares of Stock
www.americanbankingnews.com - November 6 at 6:58 PM
Vertex Pharma (VRTX) Says Phase 3 Studies of Tezacaftor/Ivacaftor Combination in People with CF Ages 12 and Older Published in NEJMVertex Pharma (VRTX) Says Phase 3 Studies of Tezacaftor/Ivacaftor Combination in People with CF Ages 12 and Older Published in NEJM
www.streetinsider.com - November 5 at 1:44 AM
Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of MedicinePhase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine
finance.yahoo.com - November 5 at 1:44 AM
Vertex Pharma (VRTX) Says Phase 3 Studies of Tezacaftor/Ivacaftor Combination in People with CF Ages 12 and Older ... - StreetInsider.comVertex Pharma (VRTX) Says Phase 3 Studies of Tezacaftor/Ivacaftor Combination in People with CF Ages 12 and Older ... - StreetInsider.com
www.streetinsider.com - November 4 at 6:18 AM
Vertex to Present at the Credit Suisse Healthcare Conference on November 7Vertex to Present at the Credit Suisse Healthcare Conference on November 7
finance.yahoo.com - November 2 at 8:58 PM
Why Vertex Pharmaceuticals Incorporated (VRTX) Delivered An Inferior ROE Compared To The IndustryWhy Vertex Pharmaceuticals Incorporated (VRTX) Delivered An Inferior ROE Compared To The Industry
finance.yahoo.com - November 2 at 8:58 PM
ETFs with exposure to Vertex Pharmaceuticals, Inc. : November 2, 2017ETFs with exposure to Vertex Pharmaceuticals, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 3:55 PM
Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis ResearchersVertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers
finance.yahoo.com - November 1 at 10:37 AM
Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017
finance.yahoo.com - November 1 at 10:37 AM
Vertex Pharmaceuticals Incorporated (VRTX) COO Ian F. Smith Sells 75,000 SharesVertex Pharmaceuticals Incorporated (VRTX) COO Ian F. Smith Sells 75,000 Shares
www.americanbankingnews.com - October 31 at 8:28 PM
Vertex Pharmaceuticals Incorporated (VRTX) EVP Amit Sachdev Sells 40,000 SharesVertex Pharmaceuticals Incorporated (VRTX) EVP Amit Sachdev Sells 40,000 Shares
www.americanbankingnews.com - October 31 at 8:28 PM
Jeffrey Chodakewitz Sells 60,000 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockJeffrey Chodakewitz Sells 60,000 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock
www.americanbankingnews.com - October 31 at 8:28 PM
Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells 6,290 Shares of StockInsider Selling: Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells 6,290 Shares of Stock
www.americanbankingnews.com - October 31 at 8:26 PM
Vertex Pharmaceuticals Incorporated Forecasted to Earn Q1 2018 Earnings of $0.30 Per Share (VRTX)Vertex Pharmaceuticals Incorporated Forecasted to Earn Q1 2018 Earnings of $0.30 Per Share (VRTX)
www.americanbankingnews.com - October 30 at 7:56 AM
Vertex Pharmaceuticals Incorporated Forecasted to Earn Q4 2017 Earnings of $0.23 Per Share (VRTX)Vertex Pharmaceuticals Incorporated Forecasted to Earn Q4 2017 Earnings of $0.23 Per Share (VRTX)
www.americanbankingnews.com - October 30 at 5:44 AM
Royal Bank Of Canada Reaffirms Buy Rating for Vertex Pharmaceuticals Incorporated (VRTX)Royal Bank Of Canada Reaffirms Buy Rating for Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - October 28 at 10:08 AM
Biotech Gets Crushed by…Celgene?Biotech Gets Crushed by…Celgene?
finance.yahoo.com - October 28 at 8:25 AM
Edited Transcript of VRTX earnings conference call or presentation 25-Oct-17 8:30pm GMTEdited Transcript of VRTX earnings conference call or presentation 25-Oct-17 8:30pm GMT
finance.yahoo.com - October 28 at 8:25 AM
Vertex Pharmaceuticals’ Performance in 3Q17Vertex Pharmaceuticals’ Performance in 3Q17
finance.yahoo.com - October 28 at 8:25 AM
Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the PipelineVertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline
www.fool.com - October 27 at 8:29 PM
Vertex Pharmaceuticals Incorporated (VRTX) Given Hold Rating at HC WainwrightVertex Pharmaceuticals Incorporated (VRTX) Given Hold Rating at HC Wainwright
www.americanbankingnews.com - October 26 at 5:24 PM
Maxim Group Reiterates Buy Rating for Vertex Pharmaceuticals Incorporated (VRTX)Maxim Group Reiterates Buy Rating for Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - October 26 at 8:34 AM
Vertex Pharmaceuticals Incorporated (VRTX) Releases  Earnings Results, Beats Expectations By $0.16 EPSVertex Pharmaceuticals Incorporated (VRTX) Releases Earnings Results, Beats Expectations By $0.16 EPS
www.americanbankingnews.com - October 25 at 7:20 PM
Vertex Pharmaceuticals Incorporated (VRTX) Receives Consensus Rating of "Buy" from AnalystsVertex Pharmaceuticals Incorporated (VRTX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 25 at 8:45 AM
Vertex Pharmaceuticals Incorporated (VRTX) Downgraded to Hold at Zacks Investment ResearchVertex Pharmaceuticals Incorporated (VRTX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 24 at 2:22 PM
A Foolish Take: The Best-Performing S&P 500 Stock This YearA Foolish Take: The Best-Performing S&P 500 Stock This Year
finance.yahoo.com - October 24 at 12:09 PM
Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VRTX-US : October 24, 2017Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VRTX-US : October 24, 2017
finance.yahoo.com - October 24 at 12:09 PM
Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)
finance.yahoo.com - October 24 at 12:09 PM
Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTXDrug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX
finance.yahoo.com - October 24 at 12:09 PM
Vertex Pharmaceuticals (VRTX) a Buy on Solid Earnings MomentumVertex Pharmaceuticals (VRTX) a Buy on Solid Earnings Momentum
investorplace.com - October 23 at 4:39 PM
Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their FamiliesVertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families
finance.yahoo.com - October 23 at 8:59 AM
4 of the Most Efficient Stocks to Buy Now4 of the Most Efficient Stocks to Buy Now
finance.yahoo.com - October 20 at 4:30 PM
 Brokerages Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Quarterly Sales of $518.45 Million Brokerages Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Quarterly Sales of $518.45 Million
www.americanbankingnews.com - October 20 at 11:38 AM

Social Media

Financials

Chart

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.